ArticleCureus2025
Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Refractory Upper Gastrointestinal Bleeding: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While resuscitative endovascular balloon occlusion of the aorta (REBOA) is a recognized life-saving intervention for hemorrhagic control in trauma, evidence supporting its use in managing refractory upper gastrointestinal bleeding (UGIB) is still limited. However, REBOA holds considerable potential for providing crucial hemodynamic stabilization in refractory UGIB cases where conventional therapies fail to achieve adequate hemostasis. We present cases of three elderly patients (88F, 72M, 74M) with refractory UGIB and profound hemorrhagic shock unresponsive to initial resuscitation. REBOA was emergently deployed at the bedside in the intensive care unit (ICU) using anatomical landmarks and ultrasound guidance, achieving rapid circulatory stabilization and enabling subsequent definitive hemostasis by surgical or endoscopic methods. No REBOA-related complications such as organ dysfunction or ischemia were observed. Our experience suggests REBOA may serve as a safe and effective bridge to hemostasis in select patients with refractory UGIB, even when deployed in an ICU setting without angiography. Further research is needed to establish standardized protocols and define optimal patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.